Clinical trials of cellular therapies to treat or prevent posttransplant relapse
| Trial name or ClinicalTrials.gov ID . | Investigational agent . | Disease . | Treatment setting . | Clinical endpoint . |
|---|---|---|---|---|
| GALAXY33 NCT05662904 | CRISPR/Cas9-based CD33 inactivated HSC+gemtuzumab | Relapsed CD33+AML after alloSCT | Salvage | Engraftment of gene-edited HSC |
| NCT05015426 | Gamma Delta T-cell | High-risk of AML recurrence after alloSCT | Prophylaxis | MTD Leukemia-free survival |
| KDS-1001 NCT05115630 | Off-the-shelf Third-party NK cells | AML, MDS, CML | Prophylaxis | NK cell related toxicities OS/DFS/GRFS |
| VCAR33 NCT05984199 | Donor-derived anti-CD33 CAR-T | Relapsed AML after HLA matched alloSCT | Salvage | DLT Response rate, GVHD, OS, PFS |
| AMpLify NCT06128044 | CRISPR-edited Allogeneic anti-CLL-1 CAR-T (CB-012) | Relapsed or refractory AML | Salvage | DLT ORR |
| NCT05473910 | Genetically engineered donor-derived T-cells targeting HA-1 (TSC-100) and HA-2 (TSC-101) | AML, MDS, ALL following haploidentical donor alloSCT | Prophylaxis | DLT OS, DFS, relapse rate |
| Trial name or ClinicalTrials.gov ID . | Investigational agent . | Disease . | Treatment setting . | Clinical endpoint . |
|---|---|---|---|---|
| GALAXY33 NCT05662904 | CRISPR/Cas9-based CD33 inactivated HSC+gemtuzumab | Relapsed CD33+AML after alloSCT | Salvage | Engraftment of gene-edited HSC |
| NCT05015426 | Gamma Delta T-cell | High-risk of AML recurrence after alloSCT | Prophylaxis | MTD Leukemia-free survival |
| KDS-1001 NCT05115630 | Off-the-shelf Third-party NK cells | AML, MDS, CML | Prophylaxis | NK cell related toxicities OS/DFS/GRFS |
| VCAR33 NCT05984199 | Donor-derived anti-CD33 CAR-T | Relapsed AML after HLA matched alloSCT | Salvage | DLT Response rate, GVHD, OS, PFS |
| AMpLify NCT06128044 | CRISPR-edited Allogeneic anti-CLL-1 CAR-T (CB-012) | Relapsed or refractory AML | Salvage | DLT ORR |
| NCT05473910 | Genetically engineered donor-derived T-cells targeting HA-1 (TSC-100) and HA-2 (TSC-101) | AML, MDS, ALL following haploidentical donor alloSCT | Prophylaxis | DLT OS, DFS, relapse rate |
CLL, chronic lymphocytic leukemia; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; DLT, dose limiting toxicity; GRFS, GVHD-free relapse-free survival; MTD, maximum tolerated dose.